Clinical

July 8th 2025

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.

July 8th 2025

Following 16 weeks of rezpegaldesleukin treatment in the REZOLVE-AD study, primary and key secondary end points have been met.

July 7th 2025

July 7th 2025

Advancements in B-cell therapies, including anti-CD20 and anti-CD19 monoclonal antibodies, enhance treatment efficacy and safety for multiple sclerosis and autoimmune diseases.